The Role of the ED in Treating Multiple Myeloma

Join the conversation! A multiple myeloma expert will present a live online activity on the dates listed below. Register to participate and earn 1.0 CME, CNE or CE credit.

The Role of the ED in Treating Multiple Myeloma
in the Era of Novel Immunotherapies

Monday, March 25, 2024
6:30 - 7:30 PM ET
Joshua Richter, MD

Program Overview

The introduction of CAR T-cell therapies and bispecific antibodies has transformed treatment of multiple myeloma (MM). However, these agents also pose unique safety challenges that may be unfamiliar to busy emergency department (ED) physicians. As more patients receive these immunotherapies, they may increasingly present to the ED for treatment of complications including CRS and ICANS.

ED clinicians must prepare now for this influx by increasing their ability to diagnose and mitigate immunotherapy-associated adverse events. Join one of our distinguished faculty in a live online discussion of the skills needed to manage these complex scenarios and support improved outcomes in MM patients treated with novel immunotherapies.

The discussion includes a Q&A session, take this opportunity to get your questions answered!

Faculty


Joshua Richter, MD Associate Professor of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Director of Myeloma Blavatnik Family Chelsea Medical Center at Mount Sinai New York City, New York	Larysa Sanchez, MD Associate Professor of Medicine Icahn School of Medicine at Mount Sinai New York City, New York	Monica Wattana, MD, FAAEM Associate Professor Director of Education University of Texas MD Anderson Cancer Center Houston, Texas

Agenda

The Role of the ED in Treating Multiple Myeloma in the Era of Novel Immunotherapies

Emerging Realities: Navigating the Influx of Myeloma Patients in the ED
Reimagining Myeloma Management: Embracing the Era of CAR T-cell Therapies and Bispecific Antibodies
Practical Field Guide: Monitoring and Managing MM-related Adverse Events in the ED
Conclusion: Clinical Trials in RRMM to Watch

Target Audience
This activity is designed for multidisciplinary healthcare providers in the community setting, including Emergency Medicine physicians, advanced practice professionals (APPs) in the EM setting and associated multidisciplinary care clinicians in the EM setting who provide care to patients with multiple myeloma.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

Identify currently available and emerging classes of novel immunotherapies for relapsed or refractory multiple myeloma (RRMM), focusing on CAR T-cell therapies and bispecific antibodies (BsAbs)
Identify known treatment-related adverse events (TRAEs) associated with CAR T-cell therapies and BsAbs in RRMM patients which have the potential to be seen in the Emergency Department (ED)
Correlate the incidence and prevalence of CRS and ICANS with the impact of these MM-related TRAEs
Outline practical, applied strategies and available tools that may be used to guide ED clinicians in promptly recognizing and escalating care of MM treatment-related CRS and ICANS

Accreditation

	CME Credit MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	Nursing Credit MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 24-015-171

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; Lillian McVey, Content Director; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the post-test and activity evaluation following the activity. Partial credit will not be awarded for this activity.

Participants will also receive a link to complete the post-test and evaluation 48 hours following the program.

CME, CNE, and CE Credit certificates will be emailed 4 weeks following receipt of completed requirements.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242 or [email protected]

Provided by
	This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

©2024 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 267-716-5451. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.